QuickLinks -- Click here to rapidly navigate through this documentAs filed with the Securities and Exchange Commission on October 31, 2003
Registration No. 333-68548
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
GENZYME CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts
(State or other jurisdiction
of incorporation or organization) | | 06-1047163
(I.R.S. Employer Identification Number) |
ONE KENDALL SQUARE, CAMBRIDGE, MASSACHUSETTS 02139, (617) 252-7500
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) |
PETER WIRTH
Executive Vice President and Chief Legal Officer
Genzyme Corporation
One Kendall Square
Cambridge, Massachusetts 02139
(617) 252-7500
(Name, address, including zip code, and telephone number, including area code, of agent for service) |
with copies to: |
PAUL KINSELLA
Ropes & Gray LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000 |
Genzyme Corporation previously registered for resale up to 2,633,400 shares of Genzyme General Division Common Stock (the "Shares") issuable in connection with Genzyme Corporation's acquisition of Novazyme Pharmaceuticals, Inc. As of the date of this Post-Effective Amendment, 177,699 Shares have been resold pursuant to the Registration Statement (assuming that holders of the Shares complied with their agreement to notify Genzyme Corporation upon any sale of Shares pursuant to the Registration Statement); accordingly, this Post-Effective Amendment is filed to deregister 2,455,701 Shares that were not sold pursuant to the Registration Statement.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on October 31, 2003.
| | | GENZYME CORPORATION |
|
|
By: |
/s/ MICHAEL S. WYZGA
Michael S. Wyzga
Executive Vice President, Finance
and Chief Financial Officer |
QuickLinks
SIGNATURES
